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To the Editor: 
 
In response:  
We thank those submitting letters. It is important to critically review COVID-19 experience 
in a peer-reviewed, non-politicized process and we fully support appropriately powered 
double-blind randomized trials to address questions on COVID-19 clinical management (1).  
Many letters discussed several similar points which we will address jointly. Corticosteroids 
(MPD) were controlled for in the multivariate and propensity analyses as were age, co-
morbidities: including cardiac disease and severity of illness. Age was an independent risk 
factor associated with mortality. We do feel that steroids have a role in reducing mortality 
for COVID-19 and were first to publish this (1), however in this study, HCQ was 
independently associated with decreased mortality, distinct benefit from the steroid effect. 
We agree with Wiseman that prospective evaluation of a stage-and-age-nuanced approach 
to COVID-19 that exploits the multiple mechanisms of HCQ and a synergy with MPD is 
needed. In response to Malviya, we reported 91% of all patients began treatment within two 
days of admission. We agree that early therapy is of most benefit, however, we do not have 
information on duration of symptoms prior to hospitalization. The mSOFA has been 
validated in other studies (2,3), moreover, we also used hypoxia as an independent marker 
of disease severity. In response to Thornton, HCQ was used throughout the study period, 
limiting time bias. We used dosages that followed FDA guidelines, with monitoring for 
cardiac arrythmias. All centers used the same treatment guideline minimizing treatment 
bias. The protocol we used was previously published (1). In response to Atkinson, patients 
assigned to HCQ group had moderate and severe illness at presentation, which would favor 
worse outcome with HCQ. The exclusion of patients with premorbid risk for cardiac toxicity 
is similar to clinical trials of many other drugs such as of remdesivir, where individuals with 
severe liver or kidney disease were excluded (4).  
 
Importantly, in response to Rosenberg, our study differed from other studies including 
randomized controlled trials (RCTs) in a variety of ways, including number of patients, 
comorbidities, severity of illness and dosage and timing of administration of HCQ (5-7). Prior 
studies have major limitations with timing, dosing, cardiac AE monitoring, and therapeutic 
windows. To date, there has been no properly designed and powered RCT that evaluates 
HCQ treatment for COVID-19. In relation to our comments about the Rosenberg paper, there 
are a variety of serious limitations in that paper that should be corrected on the record. The 
key limitation among many others are that patients receiving HCQ with or without 
azithromycin (AZM) were overall sicker on presentation and had multiple other risk factors; 
Black or Hispanic patients were likely to receive HCQ or AZM (mortality is significantly 
higher in these groups). Patients receiving HCQ were more likely to be obese, diabetic, have 
chronic lung disease, and cardiovascular conditions; yet these sicker patients had 
approximately the same mortality rates compared to patients with a milder course of the 
disease and less risk factors. However, the authors conclude that "there are no significant 
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benefits." It is noteworthy that HCQ was associated with a significant survival benefit in a 
larger cohort of patients from New York City as reported by Mikami et al (7).  
 
In these unprecedented times, the role, cost benefit, and availability of repurposed agents 
such as HCQ and newer drugs such as remdesivir should be urgently evaluated in an 
impartial manner. Remdesivir is a novel drug with a novel approach and has a place in the 
COVID-19 treatment formulary, however it is expensive and there is limited availability 
outside of the United States (8). 
 
The overarching theme in our paper is that a safe dosage and early utilization of 
hydroxychloroquine reduced mortality in hospitalized patients. Similar published large 
cohort studies support our findings from New York City and France (7, 10) As stated in our 
paper, further prospective studies are needed. 
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